307 related articles for article (PubMed ID: 29334932)
1. Anemia in people on second line antiretroviral treatment in Lilongwe, Malawi: a cross-sectional study.
Ngongondo M; Rosenberg NE; Stanley CC; Lim R; Ongubo D; Broadhurst R; Speight C; Flick R; Tembo P; Hosseinpour MC
BMC Infect Dis; 2018 Jan; 18(1):39. PubMed ID: 29334932
[TBL] [Abstract][Full Text] [Related]
2. A cross-sectional study to evaluate second line virological failure and elevated bilirubin as a surrogate for adherence to atazanavir/ritonavir in two urban HIV clinics in Lilongwe, Malawi.
Ongubo DM; Lim R; Tweya H; Stanley CC; Tembo P; Broadhurst R; Gugsa S; Ngongondo M; Speight C; Heller T; Phiri S; Hosseinipour MC
BMC Infect Dis; 2017 Jul; 17(1):461. PubMed ID: 28673254
[TBL] [Abstract][Full Text] [Related]
3. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
Spaulding A; Rutherford GW; Siegfried N
Cochrane Database Syst Rev; 2010 Oct; (10):CD008740. PubMed ID: 20927777
[TBL] [Abstract][Full Text] [Related]
4. Zidovudine impairs immunological recovery on first-line antiretroviral therapy: collaborative analysis of cohort studies in southern Africa.
Wandeler G; Gsponer T; Mulenga L; Garone D; Wood R; Maskew M; Prozesky H; Hoffmann C; Ehmer J; Dickinson D; Davies MA; Egger M; Keiser O;
AIDS; 2013 Sep; 27(14):2225-32. PubMed ID: 23660577
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of nonsuppressed viral load and associated factors among HIV-positive adults receiving antiretroviral therapy in Eswatini, Lesotho, Malawi, Zambia and Zimbabwe (2015 to 2017): results from population-based nationally representative surveys.
Haas AD; Radin E; Hakim AJ; Jahn A; Philip NM; Jonnalagadda S; Saito S; Low A; Patel H; Schwitters AM; Rogers JH; Frederix K; Kim E; Bello G; Williams DB; Parekh B; Sachathep K; Barradas DT; Kalua T; Birhanu S; Musuka G; Mugurungi O; Tippett Barr BA; Sleeman K; Mulenga LB; Thin K; Ao TT; Brown K; Voetsch AC; Justman JE
J Int AIDS Soc; 2020 Nov; 23(11):e25631. PubMed ID: 33225559
[TBL] [Abstract][Full Text] [Related]
6. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.
Soria A; Porten K; Fampou-Toundji JC; Galli L; Mougnutou R; Buard V; Kfutwah A; Vessière A; Rousset D; Teck R; Calmy A; Ciaffi L; Lazzarin A; Gianotti N
Antivir Ther; 2009; 14(3):339-47. PubMed ID: 19474468
[TBL] [Abstract][Full Text] [Related]
7. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of anemia and correlation with biomarkers and specific antiretroviral regimens in 9690 human-immunodeficiency-virus-infected patients: findings of the Anemia Prevalence Study.
Mildvan D; Creagh T; Leitz G;
Curr Med Res Opin; 2007 Feb; 23(2):343-55. PubMed ID: 17288689
[TBL] [Abstract][Full Text] [Related]
9. Magnitude and correlates of moderate to severe anemia among adult HIV patients receiving first line HAART in Northwestern Tanzania: a cross sectional clinic based study.
Gunda DW; Kilonzo SB; Mpondo BC
Pan Afr Med J; 2016; 23():26. PubMed ID: 27200131
[TBL] [Abstract][Full Text] [Related]
10. High incidence of zidovudine induced anaemia in HIV infected patients in eastern India.
Agarwal D; Chakravarty J; Chaube L; Rai M; Agrawal NR; Sundar S
Indian J Med Res; 2010 Oct; 132():386-9. PubMed ID: 20966515
[TBL] [Abstract][Full Text] [Related]
11. Metabolic syndrome in patients on first-line antiretroviral therapy containing zidovudine or tenofovir in rural Lesotho, Southern Africa.
Labhardt ND; Müller UF; Ringera I; Ehmer J; Motlatsi MM; Pfeiffer K; Hobbins MA; Muhairwe JA; Muser J; Hatz C
Trop Med Int Health; 2017 Jun; 22(6):725-733. PubMed ID: 28342180
[TBL] [Abstract][Full Text] [Related]
12. Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients.
Masiá M; Padilla S; Bernal E; Almenar MV; Molina J; Hernández I; Graells ML; Gutiérrez F
Clin Ther; 2007 Jul; 29(7):1448-55. PubMed ID: 17825696
[TBL] [Abstract][Full Text] [Related]
13. Treatment limitations imposed by antiretroviral drug resistance mutations: implication for choices of first line regimens in resource-limited settings.
Mtambo A; Chan K; Shen A; Lima V; Hogg R; Montaner J; Moore D
HIV Med; 2012 Mar; 13(3):141-7. PubMed ID: 22107262
[TBL] [Abstract][Full Text] [Related]
14. Distribution of advanced HIV disease from three high HIV prevalence settings in Sub-Saharan Africa: a secondary analysis data from three population-based cross-sectional surveys in Eshowe (South Africa), Ndhiwa (Kenya) and Chiradzulu (Malawi).
Chihana ML; Huerga H; Van Cutsem G; Ellman T; Goemaere E; Wanjala S; Masiku C; Szumilin E; Etard JF; Maman D; Davies MA
Glob Health Action; 2019; 12(1):1679472. PubMed ID: 31679482
[No Abstract] [Full Text] [Related]
15. Noncommunicable Diseases Burden and Risk Factors in a Cohort of HIV+ Elderly Patients in Malawi.
Ciccacci F; Tolno VT; Doro Altan AM; Liotta G; Orlando S; Mancinelli S; Palombi L; Marazzi MC
AIDS Res Hum Retroviruses; 2019; 35(11-12):1106-1111. PubMed ID: 31468993
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of metabolic syndrome among antiretroviral-naive and antiretroviral-experienced HIV-1 infected Thai adults.
Jantarapakde J; Phanuphak N; Chaturawit C; Pengnonyang S; Mathajittiphan P; Takamtha P; Dungjun N; Pinyakorn S; Pima W; Prasithsirikul W; Phanuphak P
AIDS Patient Care STDS; 2014 Jul; 28(7):331-40. PubMed ID: 24914459
[TBL] [Abstract][Full Text] [Related]
17. Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières.
Pujades-Rodríguez M; O'Brien D; Humblet P; Calmy A
AIDS; 2008 Jul; 22(11):1305-12. PubMed ID: 18580610
[TBL] [Abstract][Full Text] [Related]
18. The shift in tuberculosis timing among people living with HIV in the course of antiretroviral therapy scale-up in Malawi.
Tweya H; Feldacker C; Mpunga J; Kanyerere H; Heller T; Ganesh P; Nkosi D; Kalulu M; Sinkala G; Satumba T; Phiri S
J Int AIDS Soc; 2019 Apr; 22(4):e25240. PubMed ID: 31038836
[TBL] [Abstract][Full Text] [Related]
19. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
[TBL] [Abstract][Full Text] [Related]
20. Predictors of HIV virological failure and drug resistance in Chinese patients after 48 months of antiretroviral treatment, 2008-2012: a prospective cohort study.
Kan W; Teng T; Liang S; Ma Y; Tang H; Zuohela T; Sun G; He C; Wall KM; Marconi VC; Liao L; Leng X; Liu P; Ruan Y; Xing H; Shao Y
BMJ Open; 2017 Sep; 7(9):e016012. PubMed ID: 28882911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
